Home › Modalities › Nucleic Acid

Nucleic Acid (18 companies)

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
AGIO Agios Pharmaceuticals HematologyMetabolic Rare 1 Approved $1.79B 7
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare 1 Phase 3 $3.54B 5
BEAM Beam Therapeutics HematologyMetabolic+1 Rare 3 Phase 2 $2.14B 6
CAMP Camp4 Therapeutics — 1 Phase 1 $251M 1
DYN Dyne Therapeutics MetabolicNeurology Rare 9 NDA Submitted $3.00B 10
ELTX Elicio Therapeutics Oncology 1 Phase 2 $40.5M 6
GERN Geron Oncology 3 Approved $644M 3
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare 28 Approved $4.49B 29
LXEO Lexeo Therapeutics CardiovascularNeurology Rare 1 Phase 2 $236M 12
PEPG PepGen Neurology Rare 1 Phase 2 $269M 1
PHIO Phio Pharmaceuticals Oncology 4 Phase 1 $8.6M 4
PRME Prime Medicine GI/HepatologyRespiratory Rare 2 Phase 1 $699M 3
PRQR ProQR Therapeutics MetabolicNeurology Rare 7 Phase 1 $163M 7
SRPT Sarepta Therapeutics NeurologyRespiratory Rare 9 Approved $1.58B 11
STOK Stoke Therapeutics Neurology Rare 2 Phase 3 $1.73B 2
HURA TuHURA Biosciences Oncology 3 Phase 3 $92.1M 4
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 3 Approved $230M 27
WVE Wave Life Sciences MetabolicNeurology+1 Rare 5 Phase 2 $560M 5